| Literature DB >> 35906539 |
Andreas Dalsgaard Jensen1, Lauge Østergaard2,3, Jeppe K Petersen2, Peter Graversen2, Jawad H Butt2, Henning Bundgaard2,4, Claus Moser5, Morten H Smerup6,4, Ivy S Modrau7, Kasper Iversen8,4, Niels E Bruun9, Christian Torp-Pedersen10,11,12,4, Gunnar Gislason13,14,4, Andrew Wang15, Sigurdur Ragnarsson16, Jonas A Povlsen17, Lars Køber2,4, Emil L Fosbøl2.
Abstract
BACKGROUND: Valve surgery guidelines for infective endocarditis (IE) are unchanged over decades and nationwide data about the use of valve surgery do not exist.Entities:
Keywords: Cardiac valve surgery; Epidemiology; Infective endocarditis; Temporal trend
Mesh:
Year: 2022 PMID: 35906539 PMCID: PMC9336053 DOI: 10.1186/s12872-022-02761-z
Source DB: PubMed Journal: BMC Cardiovasc Disord ISSN: 1471-2261 Impact factor: 2.174
Fig. 1Flowchart of patient inclusion. Percentage marked with “*” is calculated as the number of patients with valve surgery per calendar period relative to the total number of patients per calendar period
Baseline characteristics
| First-time diagnosis of infective endocarditis (IE) between 1999 and 2018 | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall (100%) | Valve surgery during admission | No valve surgery during admission | |||||||||
| 1999–2018 | 1999–2003 | 2004–2008 | 2009–2013 | 2014–2018 | 1999–2003 | 2004–2008 | 2009–2013 | 2014–2018 | |||
| < 40 years | 596 (6.8%) | 48 (13.3%) | 42 (8.7%) | 49 (8.9%) | 48 (8.2%) | 0.024 | 124 (11.1%) | 109 (7.1%) | 92 (5.1%) | 84 (3.5%) | < 0.001 |
| 40–49 years | 613 (7.0%) | 47 (13.1%) | 57 (11.8%) | 69 (12.5%) | 49 (8.4%) | 0.031 | 93 (8.3%) | 106 (6.9%) | 103 (5.7%) | 89 (3.7%) | < 0.001 |
| 50–59 years | 1107 (12.6%) | 90 (25.0%) | 113 (23.4%) | 109 (19.7%) | 97 (16.6%) | < 0.001 | 133 (11.9%) | 161 (10.5%) | 183 (10.2%) | 221 (9.3%) | 0.017 |
| 60–69 years | 1893 (21.5) | 90 (25.0%) | 152 (31.5%) | 169 (30.6%) | 165 (28.2%) | 0.561 | 200 (17.9%) | 293 (19.2%) | 393 (21.8%) | 431 (18.1%) | 0.902 |
| 70–79 years | 2627 (29.8) | 76 (21.1%) | 103 (21.3%) | 133 (24.1%) | 199 (34.0%) | < 0.001 | 342 (30.7%) | 450 (29.5%) | 515 (28.6%) | 809 (34.0%) | 0.013 |
| > 79 years | 1968 (22.4%) | 9 (2.5%) | 16 (3.3%) | 24 (4.3%) | 27 (4.6%) | 0.071 | 223 (20.0%) | 409 (26.8%) | 516 (28.6%) | 744 (31.3%) | < 0.001 |
| Age (median, 25–75th percentile) | 70.8 (59.2–79.1) | 59.7 (49.6–69.1) | 62.2 (52.3–69.8) | 63.1 (52.3–71.6) | 66.9 (55.2- 73.0) | < 0.001 | 70.2 (55.2, 78.3) | 72.4 (60.2, 80.5) | 72.6 (63.0, 81.2) | 74.8 (65.8, 81.7) | < 0.001 |
| Male | 5762 (65.4%) | 244 (67.8%) | 352 (72.9%) | 431 (77.9%) | 425 (72.6%) | 0.008 | 640 (57.4%) | 935 (61.2%) | 1208 (67.0%) | 1525 (64.1%) | < 0.001 |
| Length of hospital admission (days, median, 25–75th percentile) | 42.0 (29.0, 52.0) | 55.0 (41.0–72.0) | 49.0 (38.0–66.0) | 48.0 (40.0–64.0) | 45 .0 (35.0–56.0) | < 0.001 | 39.0 (27.0–51.0) | 41.0 (26.0–52.0) | 39.0 (26.0–50.0) | 35.0 (25.0–47.0) | < 0.001 |
| Days from admission until surgery (days, median, 25–75th percentile) | – | 18.5 (8.0–34.0) | 13.0 (5.0–25.0) | 9.0 (4.0–20.0) | 6.0 (3.0–13.0) | < 0.001 | – | – | – | – | – |
| Extraction of a previously implanted CIED and valve surgery | 21 (0.2%) | < 4 (< 1.1%) | < 4 (< 0.8%) | 6 (1.1%) | 11 (1.9%) | 0.011 | – | – | – | – | – |
| Presumed isolated RS-IE1 | 466 (5.3%) | – | – | – | – | – | 33 (3.0%) | 68 (4.5%) | 157 (8.7%) | 208 (8.7%) | < 0.001 |
| Of them, extraction of a previously implanted CIED and no valve surgery | 367 (78.8%) | – | – | – | – | – | 4 (12.1%) | 50 (7.4%) | 133 (84.7%) | 180 (86.5%) | < 0.001 |
| Of them, more than half of admission at an infectious disease ward and no valve surgery | 99 (21.4%) | – | – | – | – | – | 29 (87.9%) | 18 (26.5%) | 24 (15.3%) | 28 (13.5%) | 0.314 |
| Prosthetic heart valve (prior to admission) | 1450 (16.5%) | 26 (7.2%) | 50 (10.4%) | 93 (16.8%) | 117 (20.0%) | < 0.001 | 78 (7.0%) | 212 (13.9%) | 346 (19.2%) | 528 (22.2%) | < 0.001 |
| Of them, number, and proportion of TAVI | 176 (12.1%) | 0 (0.0%) | 0 (0.0%) | < 4 (< 4.3%) | 5 (4.3% | 0.012 | 0 (0.0%) | 0 (0.0%) | 33 (9.5%) | 136 (25.8%) | < 0.001 |
| Diabetes | 1739 (19.8%) | 34 (9.4%) | 47 (9.7%) | 85 (15.4%) | 105 (17.9%) | < 0.001 | 145 (13.0%) | 258 (16.9%) | 406 (22.5%) | 659 (27.7%) | < 0.001 |
| Renal disease | 1159 (13.2%) | 20 (5.6%) | 31 (6.4%) | 50 (9.0%) | 53 (9.1%) | 0.020 | 84 (7.5%) | 178 (11.6%) | 300 (16.6%) | 443 (18.6%) | < 0.001 |
| Dialysis2 | 495 (5.6%) | 7 (1.9%) | 14 (2.9%) | 26 (4.7%) | 24 (4.1%) | 0.042 | 28 (2.5%) | 93 (6.1%) | 134 (7.4%) | 169 (7.1%) | < 0.001 |
| Liver disease | 622 (7.1%) | 20 (5.6%) | 26 (5.4%) | 22 (4.0%) | 30 (5.1%) | 0.603 | 70 (6.3%) | 108 (7.1%) | 141 (7.8%) | 205 (8.6%) | 0.009 |
| CIED2 | 1066 (12.2%) | 4 (1.1%) | 15 (3.1%) | 26 (4.7%) | 36 (6.2%) | < 0.001 | 24 (2.2%) | 134 (8.7%) | 321 (17.8%) | 507 (21.3%) | < 0.001 |
| Atrial fibrillation/flutter | 2105 (23.9%) | 40 (11.1%) | 55 (11.4%) | 80 (14.5%) | 99 (16.9%) | 0.003 | 184 (16.5%) | 328 (21.5%) | 515 (28.6%) | 804 (33.8%) | < 0.001 |
| Congestive heart failure | 1946 (22.1%) | 41 (11.4%) | 66 (13.7%) | 80 (14.5%) | 66 (11.3%) | 0.848 | 223 (20.0%) | 345 (22.6%) | 486 (27.0%) | 639 (26.9%) | < 0.001 |
| Myocardial infarction | 1014 (11.5%) | 14 (3.9%) | 26 (5.4%) | 36 (6.5%) | 38 (6.5%) | 0.081 | 106 (9.5%) | 197 (12.9%) | 265 (14.7%) | 332 (14.0%) | < 0.001 |
| Disease of the mitral valve | 783 (8.9%) | 46 (12.8%) | 43 (8.9%) | 50 (9.0%) | 44 (7.5%) | 0.015 | 110 (9.9%) | 134 (8.8%) | 146 (8.1%) | 210 (8.8%) | 0.374 |
| Disease of the aortic valve | 2296 (26.1%) | 63 (17.5%) | 112 (23.2%) | 155 (28.0%) | 195 (33.3%) | < 0.001 | 191 (17.1%) | 314 (20.5%) | 510 (28.3%) | 756 (31.8%) | < 0.001 |
| Ischemic/haemorrhagic stroke | 1061 (12.0%) | 14 (3.9%) | 33 (6.8%) | 45 (8.1%) | 52 (8.9%) | 0.004 | 103 (9.2%) | 180 (11.8%) | 265 (14.7%) | 369 (15.5%) | < 0.001 |
| Chronic obstructive lung disease | 1054 (12.0%) | 18 (5.0%) | 32 (6.6%) | 43 (7.8%) | 45 (7.7%) | 0.102 | 130 (11.7%) | 192 (12.6%) | 266 (14.8%) | 328 (13.8%) | 0.046 |
| Malignancy | 1623 (18.4%) | 37 (10.3%) | 45 (9.3%) | 57 (10.3%) | 95 (16.2%) | 0.002 | 164 (14.7%) | 270 (17.7%) | 366 (20.3%) | 589 (24.8%) | < 0.001 |
| Drug abuse | 147 (1.7%) | < 4 (< 1.1%) | < 4 (< 0.8%) | 4 (0.7%) | < 4 (< 0.7%) | 0.413 | 22 (2.0%) | 27 (1.8%) | 22 (1.2%) | 26 (1.1%) | 0.017 |
| Hypertension | 4261 (48.4%) | 93 (25.8%) | 179 (37.1%) | 233 (42.1%) | 241 (41.2%) | < 0.001 | 409 (36.7%) | 750 (49.1%) | 1027 (57.0%) | 1329 (55.9%) | < 0.001 |
| Glucose lowering medication | 1351 (15.3%) | 28 (7.8%) | 37 (7.7%) | 70 (12.7%) | 82 (14.0%) | < 0.001 | 113 (10.1%) | 199 (13.0%) | 318 (17.6%) | 504 (21.2%) | < 0.001 |
| Lipid lowering medication | 2674 (30.4%) | 26 (7.2%) | 104 (21.5%) | 164 (29.7%) | 195 (33.3%) | < 0.001 | 82 (7.4%) | 387 (25.3%) | 711 (39.5%) | 1005 (42.3%) | < 0.001 |
| Oral anticoagulants | 2137 (24.3%) | 48 (13.3%) | 74 (15.3%) | 105 (18.9%) | 133 (22.7%) | < 0.001 | 178 (15.9%) | 323 (21.1%) | 458 (25.4%) | 818 (34.4%) | < 0.001 |
This table shows the associated covariates (comorbidities and pharmacotherapy) for patients with infective endocarditis per calendar period (1999–2003, 2004–2008, 2009–2013, 2014–2018) subdivided by valve surgery during admission
CIED, cardiac implantable electronic device, RS-IE, right-sided infective endocarditis
Percentage marked with “*” is calculated as the number of patients with/without valve surgery per calendar period relative to the total number of patients per calendar period
1Patients were presumed having right sided IE if more than half of their current admission was at an infectious disease ward or if they had a prior CIED and subsequently underwent an extraction during admission
2Data on dialysis and CIED was available from ≥ 2000
Fig. 2Number of IE-patients and valve surgery during admission. The figure shows the total number of patients with first-time IE with/without surgery during admission. Furthermore, the figure shows the proportion of patients with IE who undergo surgery during admission (in %) as well as the postoperative mortality (30 days, Kaplan–Meier estimates, in %)
Fig. 3The figure shows the proportion of patients with IE who underwent surgery during their admission by calendar-year by the age groups < 40 years, 40–64 years, 65–75 years, > 75 years. IE: Infective endocarditis
Odds ratio of valve surgery during admission and hazard ratio of 30 day postoperative mortality for patients with infective endocarditis in the study period 1999–2018
| Valve surgery during admission | 30 day postoperative mortality | |||
|---|---|---|---|---|
| Calendar periods | Odds ratio (95% CI) Adjusted1 | Hazard ratio (95% CI) Adjusted2 | ||
| 1999–2003 | 1.00 (ref.) | – | 1.00 (ref.) | – |
| 2004–2008 | 1.14 (0.96–1.35) | 0.133 | 0.96 (0.65–1.41) | 0.840 |
| 2009–2013 | 1.20 (1.02–1.42) | 0.030 | 0.43 (0.28–0.67) | < 0.001 |
| 2014–2018 | 1.10 (0.93–1.29) | 0.266 | 0.55 (0.37–0.83) | 0.004 |
This table shows the associated odds ratios of valve surgery and 30 day postoperative mortality when adjusting for covariates for patients with first-time infective endocarditis between 1999 and 2018
Odds Ratio > 1 = increased likelihood. Hazard ratio > 1 = increased rate. Reference (ref.)
1Model adjusted for: calendar period, age groups, sex, prior prosthetic heart valve, diabetes, renal disease, liver disease, atrial fibrillation/flutter, congestive heart failure, myocardial infarction, disease of the mitral valve, disease of the aortic valve, ischemic/haemorrhagic stroke, chronic obstructive lung disease, malignancy. 2Model adjusted for: calendar period, age (continues), sex, prior prosthetic heart valve, diabetes, renal disease, liver disease, atrial fibrillation/flutter, congestive heart failure, myocardial infarction, disease of the mitral valve, disease of the aortic valve, ischemic/haemorrhagic stroke, chronic obstructive lung disease, malignancy